You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 9, 2026

Court Judgment Reaffirms Rules on Advertising of Medical Facilities in Thailand

On August 5, 2026, the Consumer Case Division of Thailand’s Civil Court rendered a judgment in a case involving a beauty clinic that advertised acne scar treatments using claims that the clinic was operated by a specialist physician and that the treatment, allegedly involving stem cell technology, could permanently remove acne scars.

The plaintiff brought a claim against both the physician-owner and the clinic company, alleging that the advertisements were false and induced her to purchase the treatment. The court found that the clinic was liable for the false representations and that the physician-owner, as both the authorized director of the company and the medical practitioner who provided treatment, was jointly responsible.

Although the plaintiff could not fully prove all damages claimed, the court awarded compensation of THB 20,000, together with interest.

While the judgment arose from a consumer protection dispute, it serves as a valuable reminder that medical facility advertisements in Thailand are regulated and may expose clinics and healthcare providers not only to regulatory enforcement but also to civil liability from patients who rely on misleading promotional claims.

Regulatory Framework Governing Medical Facility Advertisements

Medical facility advertising in Thailand is governed by the Medical Facility Act B.E. 2541 (1998), as amended by the Medical Facility Act (No. 4) B.E. 2559 (2016).

The principal secondary legislation is the Department of Health Service Support (DoHSS) Notification Re: Rules, Procedures, Conditions, and Fees for an Advertisement or Publication Concerning a Medical Facility, which came into force on November 25, 2019. Under this notification, “advertising” includes any act, by any means, that causes members of the public to see, hear, or otherwise become aware of a message, sound, or image for the commercial benefit of a medical facility. This broad definition covers not only traditional media but also clinic websites, social media, and other digital marketing channels.

Prior Approval Requirement

Section 38 of the Medical Facility Act requires medical facilities to obtain approval from the DoHSS before publishing any advertisement relating to the facility.

The only statutory exception is where the communication contains solely the medical facility’s name and location exactly as stated in its license.

Section 38 also expressly prohibits advertisements containing false, exaggerated, deceptive, or misleading statements—regarding the medical facility’s name or location, the medical services offered, the qualifications of healthcare professionals, or the competence or capabilities of healthcare personnel—that are intended to induce individuals to use the facility’s services.

The recent acne scar treatment case demonstrates the risk associated with claims that promise specific results, represent a doctor as possessing special expertise without adequate substantiation, or suggest that a treatment can permanently cure a condition.

Advertisements Exempt from Prior Approval

The 2019 notification permits certain information to be displayed within the medical facility premises without obtaining prior approval, including:

  • Abbreviations, trade names, logos, and symbols
  • Qualifications of healthcare professionals
  • Service fees and pricing information
  • Patient rights information
  • Lists of medical services and operating hours
  • Medical and public health knowledge, research findings, and educational content (subject to prescribed warning statements)
  • Announcements concerning facility activities, relocation, destruction of records, or commemorative events

Advertisements That May Be Approved

Advertisements outside the exemption categories require approval before publication. The DoHSS may approve advertisements that contain the following promotional elements, provided specific conditions are met:

  • Free medical services. Advertisements promoting free services must clearly state the date and time, the location, and the scope of the services offered.
  • Gifts, exchanges, benefits, prizes, or lucky draws. These may be offered only if the service recipient is the direct beneficiary and the medical service provided is not below the general standard.
  • Discounts on non-medical services. These may be offered only if the service recipient is the direct beneficiary.
  • Discounts on medical services. These may be offered for a period of up to one year.

Application Procedures

The approval process depends on the location of the medical facility.

  • For facilities located in Bangkok, applications must be submitted to the Center of Healthcare Advertising Approval (CHAA) within the DoHSS. Applications may be filed in person or by post. According to the CHAA website, straightforward applications involving text or still images may be approved within approximately five to seven working days after complete documentation is submitted.
  • For facilities located outside Bangkok, applications must be submitted to the relevant Provincial Public Health Office.

Penalties for Noncompliance

Failure to obtain prior approval may result in a fine of up to THB 20,000 and an additional daily fine of up to THB 10,000 for failure to comply with an order requiring the advertisement to be removed.

Advertisements that are false, exaggerated, deceptive, or misleading carry more severe penalties: imprisonment of up to one year, a fine of up to THB 20,000, or both. Additional daily fines of up to THB 10,000 may also be imposed until the offending advertisement is withdrawn.

Increased Enforcement Against Repeat Offenders

According to recent statements from the DoHSS, enforcement against repeat offenders is becoming increasingly stringent. The department reportedly applies an escalating penalty approach:

  • First violation: approximately 25 percent of the maximum fine
  • Second violation: approximately 50 percent
  • Third violation: approximately 75 percent
  • Fourth violation: referral for criminal prosecution

Importantly, the authority currently considers each advertising platform separately. In other words, violations are generally assessed by channel rather than by the number of individual posts. However, authorities have indicated that future enforcement may consider each prohibited claim separately, potentially increasing exposure significantly, including the risk that serious or repeated violations may give rise not only to civil claims but also to criminal complaints or prosecution.

The DoHSS is also reportedly considering introducing informer reward mechanisms for advertising violations, although the proposal remains under review. If adopted, such mechanisms could further increase the likelihood of complaints being filed, including potential criminal complaints in cases involving false, exaggerated, deceptive, or misleading advertising.

As enforcement activity continues to increase, the distinction between aggressive marketing and unlawful advertising is becoming increasingly important. A misleading claim may not only result in regulatory penalties but may also expose the clinic, its directors, and treating healthcare professionals to civil claims from dissatisfied patients and, where the facts support it, to criminal complaints or prosecution under the applicable statutory framework.

RELATED INSIGHTS​ 

October 15, 2025
The Indonesian Food and Drug Administration (BPOM) has introduced more stringent oversight of health supplements containing probiotics with new guidelines that require clinical trials for certain products and expanded documentation standards. BPOM Regulation No. 17 of 2025 replaces the previous 2021 regulation and establishes a comprehensive framework for evaluating probiotic strains used in health supplements. Assessment Requirements The new regulation expands the scope of assessment to include not only categorization and documentation but also technical procedures, strain classification, and clinical trial requirements. Unlike the previous regulation, which provided general guidance, the updated framework creates a comprehensive system for evaluating both registered probiotic strains and new or combined strains. Manufacturers must now submit supporting documentation covering strain identification and functional characterization, safety, efficacy, and product quality. The previous regulation required documentation only on safety, efficacy, and quality. Clinical Trials One of the most significant changes is the requirement for clinical trials conducted in Indonesia for applications that include benefit claims other than maintaining digestive health, or where there are modifications to benefit claims. The regulation specifies that phase 1 trials must demonstrate safety, while phase 2 trials must validate efficacy using statistically valid methods such as double-blind, randomized, placebo-controlled studies). In addition, phase 3 and phase 4 trials may be required, and postmarket surveillance data must be submitted. Technical Assessment Framework Annex 4, a newly introduced section, establishes technical procedures for assessing health supplements containing probiotics in Indonesia. This comprehensive framework outlines criteria for evaluating new probiotic strains, including strain identification, functional characterization, safety, efficacy, and product quality. The annex introduces a clear classification of claims for health supplement products containing probiotics: General claims(e.g., maintaining digestive health). Functional claims(e.g., normal biological function or activity in the body). Risk reduction claims(e.g., lowering disease risk). The regulation restricts use of the term
October 3, 2025
On September 26, 2025, the Contract Committee under Thailand’s Consumer Protection Board issued a regulation that aims to standardize contracts and enhance consumer protection within the beauty and wellness industry. The Notification on Prescribing the Beauty Service Business as a Contract-Controlled Business B.E. 2568 (2025), which takes effect on January 24, 2026, requires business operators to use a prescribed standard contract in Thai and adhere to strict mandatory provisions and prohibitions. These regulations apply to operators across all in-person and online service channels, including via digital platforms. “Beauty services business” is defined as the provision of services under an agreement allowing consumers to receive a series of treatments, either over a set number of sessions or within a set period. This includes massage, spa, other methods for cleanliness, beauty, or care of facial or body skin, and weight control and body shaping—including services offered electronically. The law excludes surgery, liposuction, and medical treatments performed by licensed practitioners. The notification establishes the following key requirements: Mandatory contract and formatting. All contracts with consumers must use the standard contract form, in Thai, with clear, readable text (minimum font size of 2 millimeters, no more than 11 characters per inch), and include all essential terms from the annexed form. Contract execution. Contracts must be made in duplicate, with one copy given to the consumer at signing. For agreements concluded through electronic channels, the process must comply with the Electronic Transactions Act and use the same required terms. Digital platforms. Business operators who provide services facilitated through a digital platform as an intermediary are ultimately responsible for ensuring the consumer receives a compliant contract. Prohibited clauses. The law prohibits clauses that limit or exclude liability for damages to life, body, health, mind, or property resulting from breach of contract or a wrongful act;
September 16, 2025
Since Thailand formally removed Mitragyna speciosa (kratom) from the list of narcotic drugs, the country has progressed from outright prohibition to a structured, license-based regime. While the Ministry of Public Health oversees cannabis plant regulation, the Ministry of Justice (MOJ) is the regulatory authority overseeing kratom plants. For the avoidance of doubt, separate Ministry of Public Health notifications prohibit the use of kratom as a food ingredient unless a food safety evaluation has been conducted; however, this restriction does not affect trade in unprocessed leaves per se. For businesses in Thailand dealing exclusively in kratom leaves, the most consequential development is the Ministerial Regulation on the Application for Permits and Notifications for the Importation and Exportation of Kratom Leaves B.E. 2568 (2025), a bylaw of the Kratom Plant Act 2022. The ministerial regulation establishes the following notable definitions: “Kratom leaves”: Fresh or dried leaves in their natural, unprocessed state (no extracts, concentrates, or infused products). “Import/Export”: Any act of bringing kratom leaves into or out of Thailand, whether for commercial sale, industrial processing abroad, or research. Import/Export Licensing Under the Kratom Plant Act, a license is mandatory for importing or exporting kratom leaves. Individuals, juristic persons, community enterprises, and state agencies in Thailand are eligible to obtain a license to import (or a license to export) kratom leaves. Licenses are available to qualified individuals and juristic persons. Individuals must satisfy the following qualifications to be eligible for a license: Thai nationality, ≥ 20 years old, resident in Thailand. Not incompetent, quasi-incompetent, or under legal guardianship. No license suspension currently in force under the Kratom Act or Narcotics Code. No license revocation in the previous two years. No conviction under the Kratom Act or Narcotics Code within the previous two years (unless fully released from punishment). Juristic persons must satisfy
September 4, 2025
With advancements in health technology, telemedicine has taken on a wider online presence in Thailand. Under the Medical Facility Act, licensed clinics and hospitals may now diagnose, prescribe, and issue electronic prescriptions during a video call, provided they maintain patient confidentiality and proper recordkeeping. As a complementary concept, a telepharmacy allows a pharmacist to verify prescriptions, counsel patients, and dispense medication from a remote site. Hospitals, clinic chains, and some retail pharmacy groups have adopted “drive-thru” or “locker” pick-up points where drugs are bagged only after a real-time video consultation with a registered pharmacist. The clear benefits of telehealth include shorter waiting times and broader access to specialists, which is in the public interest. Drug Distribution and Advertising in Thailand The online pharmacy ecosystem creates a legal bridge in that once a teleconsulting doctor issues an e-prescription, a licensed pharmacy can lawfully dispense and deliver the medicine prescribed to the patient’s door. Nonetheless, the critical compliance component remains the advertising of medicinal drugs. It is still not allowed to advertise prescription/pharmacy-dispensed drugs to the public in Thailand. Although Thailand’s Drug Act of 1967 was written more than half a century ago, it still governs the trading of every medicinal drug that makes its way to consumers in Thailand—whether bought at a pharmacy or delivered with a few taps on a smartphone. First and foremost, the pharmacy must hold a license to sell medicinal drugs as a retailer. It is also mandatory that arrangements be made for a pharmacist to be on duty during opening hours. Drugs are classified into three main categories: prescription drugs, pharmacy-dispensed drugs, and over-the-counter (OTC) drugs. The listing of OTC drugs with their prices via an online platform is allowed, as only OTC drugs may be advertised directly to the public. However, naming or showing